Day 1 – Tuesday, February 25th | |
---|---|
08:00-08:15 | Opening Welcome and Introduction Claudio Cerchione, Italy; Hagop Kantarjian, USA; Giovanni Martinelli, Italy |
08:15-09:55 | Session 1: Multiple Myeloma – Biology Chairs: Cirino Botta, Italy, Bruno Paiva, Spain |
From research to the clinical practice: the milestones of myeloma biology Alessandra Romano, Italy |
|
Targeting the bone marrow microenvironment in multiple myeloma Cirino Botta, Italy |
|
Unmasking novel biomarkers to sketch future trajectories in multiple myeloma therapy Vanessa DeSantis, Italy |
|
Adhesion molecule interactions at the multiple myeloma interface: new insights Antonio Solimando, Italy |
|
How and when to integrate flow cytometry in daily practice of multiple myeloma Bruno Paiva, Spain |
|
How to modulate immune system in mutiple myeloma? Annamaria Gullà, Italy |
|
09:55-10:10 | Coffee Break |
10:10-11:35 | Session 2: Multiple Myeloma – Clinical Session Chairs: Claudio Cerchione, Italy, Hans Carl Lee, USA |
How I manage smoldering multiple myeloma Maria Victoria Mateos, Spain |
|
Multiple myeloma: State-of-the-art in Europe Claudio Cerchione, Italy |
|
Multiple myeloma: State-of-the-art in the USA Hans Carl Lee, USA |
|
Multiple myeloma cured in 2030: what are the next steps? Kenneth Anderson, USA |
|
Is it time for biomarkers-driven approach in smoldering and multiple myeloma? Irene Ghobrial, USA |
|
11:35-12:45 | Session 3: Multiple Myeloma – Front-line Setting Chairs: Claudio Cerchione, Italy; Angelo Maiolino, Brazil; Vittorio Montefusco, Italy |
How I manage multiple myeloma in frontline setting Vittorio Montefusco, Italy |
|
New insights and opportunities: autologous SCT as backbone in induction therapy or bispecific/CAR-T? Angelo Maiolino, Brazil |
|
How I manage extramedullary disease and plasma cell leukemia Daniele Derudas, Italy |
|
How I manage bone disease and its complications in multiple myeloma Evangelos Terpos, Greece |
|
12:45-13:00 | Break – Lunch Box Pick-up |
13:00-14:00 | New perspectives for RRMM TCR patients Industry-supported Lunch Symposium by Oncopeptides |
Prof. Claudio Cerchione: Melflufen, mechanism of action and data from clinical trials | |
Dott. Vittorio Montefusco: Therapeutic options in patients not eligible for immunotherapy | |
Prof.ssa. Alessandra Romano: Clinical cases in real world practice | |
Prof. Paul Richardson: Past, present and future of PDC | |
Discussion | |
14:00-14:10 | Short Break |
14:10-15:35 | Session 4: Multiple Myeloma – Relapsed/refractory Chairs: Francesco Di Raimondo, Italy; Renato Zambello, Italy |
How to manage early relapses Bispecific antibodies, ADC and CAR-Ts: Joshua Richter, USA Other options: Alessandra Romano, Italy |
|
How to manage heavily pretreated RRMM Francesco Di Raimondo, Italy |
|
Mechanisms of disease resistance to T-cell based therapies: a clinical perspective Paul Richardson, USA |
|
Determinants of Resistance to CAR-T and T-cell engagers in multiple myeloma Paola Neri, Canada |
|
15:35-16:50 | Session 5: Chronic Lymphocytic Leukemia Chairs: Antonio Cuneo, Italy; Alessandra Ferrajoli, USA; Gianluca Gaidano, Italy; Ahmad Ibrahim, Lebanon |
How I manage CLL At MDACC: Alessandra Ferrajoli, USA In Italy: Antonio Cuneo, Italy |
|
Which current sequencing in CLL in the real world? Gianluca Gaidano, Italy |
|
How to use novel agents in elderly CLL Ahmad Ibrahim, Lebanon |
|
What prognostic models should we use in CLL? Stefano Molica, Italy |
|
16:50-17:45 | Session 6: Hodgkin and T-Cell Lymphomas: State-of-the-art Chairs: Amanda Cashen, USA; Carmino De Souza, Brazil; Adrián Mosquera, Spain |
How I manage Hodgkin in Disease in the USA Amanda Cashen, USA |
|
Advanced-stage Hodgkin lymphoma: the end of ABVD and BEACOPP? Carmino De Souza, Brazil |
|
Decision support systems: a new paradigm in medical information Adrián Mosquera, Spain |
|
17:45-19:30 | Session 7: Non-Hodgkin Lymphomas: State-of-the-art Chairs: Andrés Ferreri, Italy; Stefano Luminari, Italy; Gerardo Musuraca, Italy |
How I manage follicular lymphoma Stefano Luminari, Italy |
|
How I manage marginal zone lymphoma Luca Arcaini, Italy |
|
Current and future therapeutic approach in first line in DLBCL Umberto Vitolo, Italy |
|
How I manage RR in DLBCL Gerardo Musuraca, Italy |
|
How I manage CNS lymphomas Andrés Ferreri, Italy |
|
How I manage aggressive lymphomas in elderly patients Raúl Córdoba, Spain |
|
How to integrate academic CAR-T in daily treatment of hematologic malignancies Julio Delgado, Spain |
|
19:30-20:45 | Session 8: Allogenic SCT in Hematological Malignancies: Dead, or Alive and Kicking? Chairs: Massimo Dominici, Italy; Jean El Cheikh, Lebanon; Filippo Milano, USA; Arnon Nagler, Israel |
Towards the future CAR-T as standard of care: Nitin Jain, USA Allogenic SCT as standard of care: Arnon Nagler, Israel |
|
New conditioning regimen pre-allogenic SCT in hematologic malignancies Jean El Cheikh, Lebanon |
|
Life after CAR-T Jose Maria Ribera, Spain |
|
How to develop an innovative cellular therapies center: from clinical trials to real-world data Filippo Milano, USA |
|
20:45 | Conclusions Day 1 Claudio Cerchione, Italy, Giovanni Martinelli, Italy |
Day 2 – Wednesday, February 26th | |
---|---|
08:00-08:20 | Welcome to Day 2 Claudio Cerchione, Italy, Giovanni Martinelli, Italy |
08:20-09:20 | Session 9: CAR-T and Cellular Therapies in Hematological Malignancies: From Dream to Reality Chairs: Giuliano Bolondi, Italy; Julio Delgado, Spain; Massimiliano Mazza, Italy |
From the preclinical to the production stage: a CAR for T-cell malignancies Massimiliano Mazza, Italy |
|
Balancing efficacy and toxicity in CAR-T and bispecific antibodies-based therapies: the point of view from the reanimation room Giuliano Bolondi, Italy |
|
CAR-T– from research to clinical applications In solid tumors: Massimo Dominici, Italy In hematology: Franco Locatelli, Italy |
|
09:20-10:15 | Session 10: Acute Lymphoblastic Leukemia – Clinical Session Chairs: Claudio Cerchione, Italy; Giovanni Martinelli, Italy |
How I manage ALL at MDACC Hagop Kantarjian, USA |
|
How I manage Elderly ALL at MDACC Elias Jabbour, USA |
|
How I manage ALL in Europe Giovanni Martinelli, Italy |
|
10:15-10:35 | Coffee Break |
10:35-12:00 | Session 11: Acute Myeloid Leukemia – State-of-the-art Chairs: Claudio Cerchione, Italy; Giovanni Martinelli, Italy |
How I manage AML at the MDACC Hagop Kantarjian, USA |
|
Non-Intensive treatment of elderly/unfit patients with AML at MDACC Tapan Kadia, USA |
|
Past, present and future of FLT3 inhibitors in AML: moving towards cure Giovanni Martinelli, Italy |
|
How I manage IDH-mutated AML at MDACC Courtney DiNardo, USA |
|
TP53 mutated AML – where are we? Naval Daver, USA |
|
12:00-13:10 | Session 12: Acute Myeloid Leukemia – Special Entities Chairs: Brunangelo Falini, Italy; Giovanni Martinelli, Italy |
Is all oral therapy of AML a reality for the future? Farhad Ravandi, USA |
|
How I manage secondary AML Alessandro Isidori, Italy |
|
Targeted therapy of NPM1-mutated AML Brunangelo Falini, Italy |
|
TP53 in myeloid leukemias: targeting the guardian of the genome Michael Andreeff, USA |
|
13:10-13:40 | Lunch Break |
13:40-15:00 | Session 13: Acute Myeloid Leukemia – Clinical Session Chairs: Sara Galimberti, Italy; Mauricette Michallet, France |
How I manage BPDCN Naveen Pemmaraju, USA |
|
The pathogenesis of acute leukemias: approaches and molecular insights Ilaria Iacobucci, USA |
|
Digital droplet PCR in hematologic malignancies: a new useful molecular tool Sara Galimberti, Italy |
|
Therapy-related AML: CHIP documentation in cancer, new perspectives in prognosis and treatment Mauricette Michallet, France |
|
15:00-15:15 | Special lecture: Role of AI in Diagnostics Torsten Haferlach, Germany |
15:15-15:30 | SOHO Insights Roundtable: Acute Myeloid and Lymphoblastic Leukemia Nicola Stefano Fracchiolla, Italy; Michele Gottardi, Italy; Carmelo Gurnari, Italy; Francesco Lanza, Italy; Federico Lussana, Italy; Agostino Tafuri, Italy; Calogero Vetro, Italy; Daniele Vallisa, Italy |
15:30-16:25 | Session 14: Myeloproliferative Neoplasms – State-of-the-art Chairs: Hanan Hamed, Egypt; Alessandro Lucchesi, Italy; Tariq Mughal, UK |
Novel combination and JAK and non-JAK inhibitor therapies on the horizon Tariq Mughal, UK |
|
Neutrophilia other than CML Hanan Hamed, Egypt |
|
A new pathogenetic paradigm for MPN: the “circulating wound” Alessandro Lucchesi, Italy |
|
16:25-17:10 | Session 15: Chronic Myeloid Leukemia – State-of-the-art Chairs: Claudio Cerchione, Italy; Carlo Gambacorti-Passerini, Italy |
How I manage CML at MDACC Elias Jabbour, USA |
|
CML history: the transition from interferon to TKI therapy Carlo Gambacorti-Passerini, Italy |
|
Stopping therapy (TFR) from clinical trials to real world – which patients, when and how to monitor Gianantonio Rosti, Italy |
|
17:10-17:25 | SOHO Insights Roundtable – CML and MPN Massimo Breccia, Italy; Paola Guglielmelli, Italy; Nicola Polverelli, Italy |
17:25-18:25 | Session 16: Myelodysplastic Syndromes – State-of-the-art Chairs: Esther Oliva, Italy; Matteo Della Porta, Italy; Phillip Scheinberg, USA |
Progress in medical therapy in aplastic anemia: why it took so long? Phillip Scheinberg, USA |
|
A practical approach to molecular pathology of myelodysplastic syndromes Matteo Della Porta, Italy |
|
How I treat lower-risk myelodysplastic syndromes Esther Oliva, Italy |
|
Is a personalized treatment approach possible for myelodysplastic syndromes: when is the optimal time for a transplant? Elena Crisà, Italy |
|
18:25-18:40 | SOHO Insights Roundtable – Myelodysplastic Syndromes Carlo Finelli, Italy |
18:40-19:55 | Session 17: Spotlights on Rare Entities and Non-Malignant Diseases Chairs: Domenico Girelli, Italy; Valeh Huseynov, Azerbaijan; Hans Carl Lee, USA; Arcangelo Liso, Italy |
How I manage Waldenstrom’s Macroglobulinemia in the era of novel agents Steven Treon, USA |
|
How I manage AL amyloidosis at MDACC Hans Carl Lee, USA |
|
How I manage advanced systemic mastocytosis Daniela Cilloni, Italy |
|
New Insights in iron deficiency anemia Domenico Girelli, Italy |
|
New insights in transfusion medicine Valeh Huseynov, Azerbaijan |
|
19:55-20:10 | SOHO Insights Roundtable – Rare Entities and Non-Malignant Diseases Arcangelo Liso, Italy; Alessandra Romano, Italy |
20:10 | Conclusions. See You Next Year Claudio Cerchione, Italy; Giovanni Martinelli, Italy |